IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3349
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$29M
John Fowler
Kezar Life Sciences, Inc. engages in the discovery and development of novel small molecule therapeutics. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$KZR Kezar Life Sciences, Inc. | 42 | 25 | 23 | 58 | - | - | -74.5% | -63.2% | - | - | - | - | 0.0% | 18.0x | $29M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Kezar Life Sciences, Inc. (KZR) receives a "Reduce" rating with a composite score of 41.5/100. It ranks #3349 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
John Fowler
Chief Executive Officer
Labor Force
60
25
25
62
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for KZR
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for KZR.
View All RatingsInsufficient data for Financial Analysis
ROE proxy -74.5% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth N/A, 8yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Kezar Life Sciences, Inc. receives a Reduce rating from our analysis, with a composite score of 41.5/100 and 2 out of 5 stars, ranking #3349 out of 7,333 stocks. KZR's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
KZR's quality score of 25/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -74.5% (sector avg: -2.5%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
KZR registers a value score of just 23/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.60x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Kezar Life Sciences, Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -63.2% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
KZR demonstrates moderate momentum with a score of 58/100, suggesting a neutral price trend without strong directional conviction. Revenue growth data is not currently available, while a beta of 0.79 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
With a stability score of 62/100, KZR exhibits average financial resilience. Key stability metrics include a beta of 0.79 and a debt-to-equity ratio of 18.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
Kezar Life Sciences, Inc.'s short interest score of 24/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 18.00x), micro-cap liquidity risk. At $29M (micro-cap), KZR carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Kezar Life Sciences, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3349 of 7,333 overall (54th percentile). Key comparisons include ROE of -74.5% trailing the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While KZR currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (23) would have the largest impact on the composite score.
ROE 2903% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 8900% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Kezar Life Sciences, Inc. (KZR) as a Reduce with a composite score of 41.5/100 at a current price of $6.81. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in stability (62th percentile) and momentum (58th percentile), which together account for the majority of the composite score. Offsetting weakness in value (23th percentile) and quality (25th percentile) tempers our overall conviction. We assign a No Moat rating (21/100), Low uncertainty, and Poor capital allocation.
Key items to watch: valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Kezar Life Sciences, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 41.5/100 places it at rank #3349 in our full 7,333-stock universe. At $29M in market capitalization, Kezar Life Sciences, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (58th percentile) are neutral regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for Kezar Life Sciences, Inc., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $6.81, Kezar Life Sciences, Inc. is trading at a premium to fundamental value. Our value factor score of 23/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 0.6x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
A conservative balance sheet (18% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Reduce rating (composite 41.5/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Below-average quality (25th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a Low uncertainty rating to Kezar Life Sciences, Inc.. The company exhibits strong financial stability with a beta of 0.79, conservative leverage (18% D/E), and a stability factor in the 62th percentile. The predictable nature of the business model and solid financial position reduce the range of potential outcomes, giving us confidence in our fair value estimate.
Specific risk factors that inform our assessment include: weak quality scores (25th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 62th percentile and quality factor at the 25th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (18% D/E) limits balance sheet risk; above-average stability (62th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate Kezar Life Sciences, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-74.5%), weak asset returns (ROA -63.2%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Kezar Life Sciences, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Kezar Life Sciences, Inc. receives a Reduce rating with a composite score of 41.5/100 (rank #3349 of 7,333). Our quantitative framework assigns a No Moat (21/100, trend: stable), Low uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 39/100.
Our analysis does not support a constructive view on Kezar Life Sciences, Inc. at this time. The combination of limited competitive advantages, low uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Kezar Life Sciences, Inc. a meaningful economic moat, scoring 21/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10/20.
The strongest moat sources are margin superiority (10/20) and financial resilience (6.4/20). GM N/A vs sector 43%, OM N/A vs sector 1%. Interest coverage N/A. These pillars form the core of Kezar Life Sciences, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and growth durability (0.9/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Kezar Life Sciences, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 25/100 which further underscores our concern regarding earnings sustainability.
Return metrics include ROE of -74.5% and ROA of -63.2%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -74.5% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 18%. The sector median D/E is 0%, putting Kezar Life Sciences, Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
SOUTH SAN FRANCISCO, Calif., January 09, 2026--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune
Upgrades According to OTR Global, the prior rating for Generac Holdings Inc (NYSE:GNRC) was changed from Negative to Mixed. In the second quarter, Generac Hldgs showed an EPS of $1.08, compared to $2.99 from the year-ago quarter. At the moment, the stock has a 52-week-high of $186.65 and a 52-week-low of $86.29. Generac Hldgs closed at $101.71 at the end of the last trading period. According to B of A Securities, the prior rating for Trane Technologies PLC (NYSE:TT) was changed from Underperform to Neutral. Trane Technologies earned $2.68 in the second quarter, compared to $2.16 in the year-ago quarter. At the moment, the stock has a 52-week-high of $211.58 and a 52-week-low of $139.19. Trane Technologies closed at $200.39 at the end of the last trading period. For UWM Holdings Corp (NYSE:UWMC), BTIG upgraded the previous rating of Neutral to Buy. UWM Hldgs earned $0.11 in the second quarter, compared to $0.10 in the year-ago quarter. The current stock performance of UWM Hldgs shows a 52-week-high of $6.98 and a 52-week-low of $2.85. Moreover, at the end of the last trading period, the closing price was at $4.67. B of A Securities upgraded the previous rating for Parker Hannifin Corp (NYSE:PH) from Neutral to Buy. For the fourth quarter, Parker Hannifin had an EPS of $6.08, compared to year-ago quarter EPS of $5.16. The current stock performance of Parker Hannifin shows a 52-week-high of $428.16 and a 52-week-low of $244.94. Moreover, at the end of the last trading period, the closing price was at $384.59. For Grupo Televisa SAB (NYSE:TV), B of A Securities upgraded the previous rating of Neutral to Buy. In the first quarter, Grupo Televisa showed an EPS of $0.07, compared to $0.18 from the year-ago quarter. The stock has a 52-week-high of $6.57 and a 52-week-low of $2.77. At the end of the last trading period, Grupo Televisa closed at $2.92. For America Movil SAB de CV (NYSE:AMX), B of A Securities upgraded the previous rating of Neutral to Buy. America Movil earned $0.46 in the second quarter, compared to $0.21 in the year-ago quarter. At the moment, the stock has a 52-week-high of $23.07 and a 52-week-low of $16.14. America Movil closed at $16.89 at the end of the last trading period. Needham upgraded the previous rating for Ceridian HCM Holding Inc (NYSE:CDAY) from Hold to Buy. Ceridian HCM Holding earned $0.32 in the second quarter, compared to $0.21 in the year-ago quarter. The stock has a 52-week-high of $79.66 and a 52-week-low of $51.55. At the end of the last trading period, Ceridian HCM Holding closed at $69.05. For Pinnacle West Capital Corp (NYSE:PNW), Keybanc upgraded the previous rating of Underweight to Sector Weight. Pinnacle West Capital earned $0.94 in the second quarter, compared to $1.45 in the year-ago quarter. The current stock performance of Pinnacle West Capital shows a 52-week-high of $86.03 and a 52-week-low of $59.07. Moreover, at the end of the last trading period, the closing price was at $71.74. Keybanc upgraded the previous rating for Entergy Corp (NYSE:ETR) from Sector Weight to Overweight. In the second quarter, Entergy showed an EPS of $1.84, compared to $1.78 from the year-ago quarter. The current stock performance of Entergy shows a 52-week-high of $120.73 and a 52-week-low of $87.10. Moreover, at the end of the last trading period, the closing price was at $91.02. Keybanc upgraded the previous rating for DTE Energy Co (NYSE:DTE) from Sector Weight to Overweight. DTE Energy earned $0.99 in the second quarter, compared to $0.88 in the year-ago quarter. At the moment, the stock has a 52-week-high of $122.27 and a 52-week-low of $93.85. DTE Energy closed at $97.11 at the end of the last trading period. According to Keybanc, the prior rating for CenterPoint Energy Inc (NYSE:CNP) was changed from Sector Weight to Overweight. CenterPoint Energy earned $0.28 in the second quarter, compared to $0.31 in the year-ago quarter. The stock has a 52-week-high of $31.50 and a 52-week-low of $25.03. At the end of the last trading period, CenterPoint Energy closed at $26.54. Keybanc upgraded the previous rating for CMS Energy Corp (NYSE:CMS) from Sector Weight to Overweight. CMS Energy earned $0.75 in the second quarter, compared to $0.53 in the year-ago quarter. At the moment, the stock has a 52-week-high of $65.72 and a 52-week-low of $49.87. CMS Energy closed at $52.28 at the end of the last trading period. For Prosperity Bancshares Inc (NYSE:PB), Raymond James upgraded the previous rating of Outperform to Strong Buy. Prosperity Bancshares earned $1.21 in the second quarter, compared to $1.40 in the year-ago quarter. At the moment, the stock has a 52-week-high of $78.76 and a 52-week-low of $51.37. Prosperity Bancshares closed at $52.25 at the end of the last trading period. RBC Capital upgraded the previous rating for Beacon Roofing Supply Inc (NASDAQ:BECN) from Sector Perform to Outperform. Beacon Roofing Supply earned $2.66 in the second quarter, compared to $2.80 in the year-ago quarter. The stock has a 52-week-high of $87.46 and a 52-week-low of $50.42. At the end of the last trading period, Beacon Roofing Supply closed at $75.25. For Live Oak Bancshares Inc (NYSE:LOB), JP Morgan upgraded the previous rating of Neutral to Overweight. Live Oak Bancshares earned $0.39 in the second quarter, compared to $2.16 in the year-ago quarter. At the moment, the stock has a 52-week-high of $38.37 and a 52-week-low of $17.30. Live Oak Bancshares closed at $27.36 at the end of the last trading period. For O'Reilly Automotive Inc (NASDAQ:ORLY), Citigroup upgraded the previous rating of Neutral to Buy. For the second quarter, O'Reilly Automotive had an EPS of $10.22, compared to year-ago quarter EPS of $8.78. The current stock performance of O'Reilly Automotive shows a 52-week-high of $975.72 and a 52-week-low of $705.74. Moreover, at the end of the last trading period, the closing price was at $897.20. According to Piper Sandler, the prior rating for Investar Holding Corp (NASDAQ:ISTR) was changed from Neutral to Overweight. For the second quarter, Investar Holding had an EPS of $0.67, compared to year-ago quarter EPS of $0.62. At the moment, the stock has a 52-week-high of $22.33 and a 52-week-low of $9.27. Investar Holding closed at $10.36 at the end of the last trading period. See all analyst ratings upgrades. Downgrades For Orchard Therapeutics PLC (NASDAQ:ORTX), Stifel downgraded the previous rating of Buy to Hold. For the second quarter, Orchard Therapeutics had an EPS of $0.07, compared to year-ago quarter EPS of $0.40. The stock has a 52-week-high of $8.35 and a 52-week-low of $3.60. At the end of the last trading period, Orchard Therapeutics closed at $8.14. Northland Capital Markets downgraded the previous rating for Shoals Technologies Group Inc (NASDAQ:SHLS) from Outperform to Market Perform. In the second quarter, Shoals Technologies Gr showed an EPS of $0.14, compared to $0.07 from the year-ago quarter. The current stock performance of Shoals Technologies Gr shows a 52-week-high of $32.37 and a 52-week-low of $15.40. ...Full story available on Benzinga.com
Gainers Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to also serve as the company’s Chief Privacy Officer. Neptune Wellness Solutions Inc. (NASDAQ: NEPT) shares rose 28.5% to $5.03 in pre-market trading after falling 11% on Wednesday. Neptune Wellness announced intention to spinout Sprout Organics pursuant to the Morgan Stanley agreed to transaction. Murphy Canyon Acquisition Corp. (NASDAQ: MURF) shares rose 32.4% to $17.00 in pre-market trading. Murphy Canyon Acquisition reported stockholder approval of the proposed combination with Conduit Pharmaceuticals. TradeUP Acquisition Corp. (NASDAQ: UPTD) shares jumped 24.2% to $15.22 in pre-market trading after surging 26% on Wednesday. The company announced an extension for its initial business combination deadline, depositing an aggregate of $37,432.70 into its trust account. Alliance Entertainment Holding Corporation (NASDAQ: AENT) shares gained 19.8% to $1.27 in pre-market trading after falling ...
Gainers Amyris, Inc. (NASDAQ: AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy. Rigetti Computing, Inc. (NASDAQ: RGTI) shares climbed 51.2% to $2.48 following a narrower-than-expected quarterly loss. Telesat Corporation (NASDAQ: TSAT) gained 47.2% to $12.44 after the company reported second-quarter results and tapped MDA under a $2.1 billion deal as prime satellite manufacturer of advanced Telesat Lightspeed Low Earth Orbit constellation. Proterra Inc. (NASDAQ: PTRA) jumped 37% to $0.1442 on continued volatility after the company announced it filed for Chapter 11 bankruptcy. Ouster, Inc. (NYSE: OUST) gained 28.8% to $6.57 after the company reported better-than-expected second-quarter financial results and issued Q3 revenue guidance. Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) jumped 24.3% to $7.24 after the company reported better-than-expected second-quarter financial results and raised FY23 revenue guidance above estimates. Millennium Group International Holdings Limited (NASDAQ: MGIH) gained 24% to $3.08. Innodata Inc. (NASDAQ: INOD) shares gained 23.9% to $13.22 after the company posted a narrower quarterly loss. Apyx Medical Corporation (NASDAQ: APYX) rose 23% to $5.18 following quarterly results. IonQ, Inc. (NYSE: IONQ) climbed 22% to $17.31 after the company reported second-quarter financial results. Lottery.com Inc. (NASDAQ: LTRY) rose 21.3% to $6.15. 2U, Inc. (NASDAQ: TWOU) climbed 20.5% to $3.7615. Groupon, Inc. (NASDAQ: GRPN) rose 20% to $9.12. Goldman Sachs and Credit Suisse raised their price targets on the stock. Bitdeer Technologies Group (NASDAQ: BTDR) gained 19.8% to $ 11.12 following quarterly results. MicroCloud Hologram Inc. (NASDAQ: HOLO) climbed 19.2% to $3.2055. Tango Therapeutics, Inc. (NASDAQ: TNGX) gained 18.8% to $7.77. HC Wainwright & Co. maintained Tango Therapeutics with a Buy and raised the price target from $11 to $16. Eton Pharmaceuticals, Inc. (NASDAQ: ETON) shares rose 17.9% to $3.0650 after posting upbeat second-quarter results. ModivCare Inc. (NASDAQ: MODV) gained 16.6% to $42.31. ModivCare Director Adam Gray acquired a total of 435,893 shares at an average price of $35.74. WeWork Inc. (NYSE: WE) shares rose 16.4% to $0.2157 after jumping 43% on Thursday. The stock has been volatile after the company recently said there was substantial doubt over its ability to stay in business. Arco Platform Limited ...
Upgrades For Alibaba Group Holding Ltd (NYSE:BABA), DZ Bank upgraded the previous rating of Hold to Buy. For the first quarter, Alibaba Gr Holding had an EPS of $2.40, compared to year-ago quarter EPS of $1.75. The current stock performance of Alibaba Gr Holding shows a 52-week-high of $121.30 and a 52-week-low of $58.02. Moreover, at the end of the last trading period, the closing price was at $99.21. Credit Suisse upgraded the previous rating for Himax Technologies Inc (NASDAQ:HIMX) from Neutral to Outperform. In the second quarter, Himax Techs showed an EPS of $0.01, compared to $0.44 from the year-ago quarter. At the moment, the stock has a 52-week-high of $8.70 and a 52-week-low of $4.82. Himax Techs closed at $6.55 at the end of the last trading period. According to Evercore ISI Group, the prior rating for Pinnacle West Capital Corp (NYSE:PNW) was changed from Underperform to In-Line. Pinnacle West Capital earned $0.94 in the second quarter, compared to $1.45 in the year-ago quarter. At the moment, the stock has a 52-week-high of $86.03 and a 52-week-low of $59.07. Pinnacle West Capital closed at $77.10 at the end of the last trading period. For Twilio Inc (NYSE:TWLO), Argus Research upgraded the previous rating of Hold to Buy. Twilio earned $0.54 in the second quarter, compared to $0.11 in the year-ago quarter. At the moment, the stock has a 52-week-high of $90.71 and a 52-week-low of $41.00. Twilio closed at $60.58 at the end of the last trading period. According to Exane BNP Paribas, the prior rating for Rivian Automotive Inc (NASDAQ:RIVN) was changed from Neutral to Outperform. For the second quarter, Rivian Automotive had an EPS of $1.08, compared to year-ago quarter EPS of $1.62. At the moment, the stock has a 52-week-high of $40.86 and a 52-week-low of $11.68. Rivian Automotive closed at $21.91 at the end of the last trading period. According to Benchmark, the prior rating for Rigetti Computing Inc (NASDAQ:RGTI) was changed from Hold to Buy. In the second quarter, Rigetti Computing showed an EPS of $0.13, compared to $0.09 from the year-ago quarter. The current stock performance of Rigetti Computing shows a 52-week-high of $5.89 and a 52-week-low of $0.36. Moreover, at the end of the last trading period, the closing price was at $1.64. According to Wolfe Research, the prior rating for Hubbell Inc (NYSE:HUBB) was changed from Underperform to Peer Perform. For the second quarter, Hubbell had an EPS of $4.07, compared to year-ago quarter EPS of $2.81. The stock has a 52-week-high of $340.06 and a 52-week-low of $204.31. At the end of the last trading period, Hubbell closed at $302.37. According to B of A Securities, the prior rating for Sabra Health Care REIT Inc (NASDAQ:SBRA) was changed from Underperform to Neutral. Sabra Health Care REIT earned $0.33 in the second quarter, compared to $0.39 in the year-ago quarter. At the moment, the stock has a 52-week-high of $16.57 and a 52-week-low of $10.08. Sabra Health Care REIT closed at $12.43 at the end of the last trading period. According to TD Cowen, the prior rating for Cogent Communications Holdings Inc (NASDAQ:CCOI) was changed from Market Perform to Outperform. In the second quarter, Cogent Comms Hldgs showed an EPS of $0.67, compared to $0.24 from the year-ago quarter. The stock has a 52-week-high of $75.00 and a 52-week-low of $46.88. At the end of the last trading period, Cogent Comms Hldgs closed at $65.97. According to Morgan Stanley, the prior rating for DigitalOcean Holdings Inc (NYSE:DOCN) was changed from Underweight to Equal-Weight. The current stock performance of DigitalOcean Holdings shows a 52-week-high of $53.86 and a 52-week-low of $23.39. Moreover, at the end of the last trading period, the closing price was at $35.01. See all analyst ratings upgrades. Downgrades According to Jefferies, the prior rating for Cano Health Inc (NYSE:CANO) was changed from Buy to Hold. For the second quarter, Cano Health had an EPS of $0.51, compared to year-ago quarter EPS of $0.03. The current stock performance of Cano Health shows a 52-week-high of $9.75 and a 52-week-low of $0.76. Moreover, at the end of the last trading period, the closing price was at $1.52. B of A Securities downgraded the previous rating for Triumph Group Inc (NYSE:TGI) from Buy to Underperform. In the first quarter, Triumph Group showed an EPS of $0.10, compared to $0.12 from the year-ago quarter. At the moment, the stock has a 52-week-high of $15.64 and a 52-week-low of $7.85. Triumph Group closed at $8.43 at the end of the last trading period. Wells Fargo downgraded the previous rating for Capri Holdings Ltd (NYSE:CPRI) from Overweight to Equal-Weight. For the first quarter, Capri Holdings had an EPS of $0.74, compared to year-ago quarter EPS of $1.50. The current stock performance of Capri Holdings shows a 52-week-high of $69.25 and a 52-week-low of $34.17. Moreover, at the end of the last trading period, the closing price was at $53.90. Lake Street downgraded the previous rating for One Stop Systems Inc (NASDAQ:OSS) from Buy to Hold. In the second quarter, One Stop Systems showed an EPS of $0.00, compared to $0.04 from the year-ago quarter. At the moment, the stock has a 52-week-high of $4.10 and a 52-week-low of $2.29. One Stop Systems closed at $3.22 at the end of the last trading period. Exane BNP Paribas downgraded the previous rating for Lucid Group Inc (NASDAQ:LCID) from Neutral to Underperform. Lucid Gr earned $0.40 in the second quarter, compared to $0.33 in the year-ago quarter. At the moment, the stock has a 52-week-high of $19.15 and a 52-week-low of $5.46. Lucid Gr closed at $6.78 at the end of the last trading period. For One Stop Systems Inc (NASDAQ:OSS), Noble Capital Markets downgraded the previous rating of Outperform to Market Perform. One Stop Systems earned $0.00 in the second quarter, compared to $0.04 in the year-ago quarter. The current stock performance of One Stop Systems shows a 52-week-high of $4.10 and a 52-week-low of $2.29. Moreover, at the end of the last trading period, the closing price was at $3.22. For The Joint Corp (NASDAQ:JYNT), Maxim Group downgraded the previous rating of Buy to Hold. The current stock performance of Joint shows a 52-week-high of $23.53 and a ...Full story available on Benzinga.com